- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01313026
Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation
Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation. A Randomized Cross Over Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will undergo anal physiological assessment and will then be randomized to either treatment arm. The first 12 weeks they will be optimized in the conservative treatment of their bowel function before beginning active treatment with TAI or PNE. After 8 and 4 weeks respectively, the treatment will stop and they will have a period of 4 weeks back on optimized conservative treatment before beginning active treatment in the other active arm.
Detailed records of bowel, micturition and sexual function and QoL will be obtained at regular intervals during the entire trial fase.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, 8000
- Colorectal Surgical Department P, Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Low anterior resection for rectal cancer between May 2001 and May 2011
Exclusion Criteria:
- Non-radical resection
- metastatic disease
- Chemotherapy
- Radiotherapy
- Previously treated for another cancer
- Dementia or other mental retardation/severe mental disease
- Inability to read and understand the Danish language
- Recurrent disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: PNE first
patients randomised to start with PNE stimulation over 4 weeks.
Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
|
Implantation of a nerve stimulator to stimulate the sacral nerve plexus
Other Names:
|
|
Active Comparator: TAI first
Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
|
Implantation of a nerve stimulator to stimulate the sacral nerve plexus
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
changes in LARS score
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
|
A symptom score ranging from 0 to 42 points calculated on the basis of bowel function
|
baseline, 12, 16, 20, 24 and 28 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sexual function
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
|
self-reported sexual function measured by validated questionnaires
|
baseline, 12, 16, 20, 24 and 28 weeks
|
|
Bladder function
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
|
self-reported bladder function by validated questionnaires
|
baseline, 12, 16, 20, 24 and 28 weeks
|
|
Incontinence
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
|
faecal incontinence measured by wexner score and St. Marks incontinence score
|
baseline, 12, 16, 20, 24 and 28 weeks
|
|
Patient Satisfaction
Time Frame: baseline, 12, 16, 20, 24 and 28 weeks
|
patient satisfaction measured on a VAS
|
baseline, 12, 16, 20, 24 and 28 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Katrine J. Emmertsen, MD, University of Aarhus
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LARS 001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
First Affiliated Hospital of Wenzhou Medical UniversityCompletedRectal Cancer Stage | Rectal Cancer PatientsChina
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.Active, not recruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedFatigue | Depressive Symptoms | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Psychosocial Effects of Cancer and Its Treatment | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditionsUnited States
Clinical Trials on Percutaneous nerve evaluation
-
University of ChicagoBrown University; University of California, Irvine; University of Texas; Allegheny... and other collaboratorsRecruitingOveractive Bladder | Urge Incontinence | Urgency-frequency SyndromeUnited States
-
César Fernández-de-las-PeñasCompleted
-
University of California, San DiegoCopenhagen University Hospital at Herlev; University California Academic Senate and other collaboratorsCompletedPostoperative PainUnited States
-
Universidad Complutense de MadridUniversidad Rey Juan CarlosRecruiting
-
University of Kansas Medical CenterCompleted
-
Children's Hospital of Orange CountyInnovative Health SolutionsRecruitingCOVID-19 | Post-Concussion Syndrome | COVID Long-HaulUnited States
-
Universidad Europea de MadridCompleted
-
Medical College of WisconsinRecruitingCyclic Vomiting SyndromeUnited States
-
Queen Mary University of LondonCompletedBowel Incontinence | Faecal Incontinence
-
Indiana UniversityNot yet recruitingDiabetes | GastroparesisUnited States